| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IL22RA2 |
| Uniprot No | Q969J5 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 22-263aa |
| 氨基酸序列 | TQSTHESLK PQRVQFQSRN FHNILQWQPG RALTGNSSVY FVQYKIMFSC SMKSSHQKPS GCWQHISCNF PGCRTLAKYG QRQWKNKEDC WGTQELSCDL TSETSDIQEP YYGRVRAASA GSYSEWSMTP RFTPWWETKI DPPVMNITQV NGSLLVILHA PNLPYRYQKE KNVSIEDYYE LLYRVFIINN SLEKEQKVYE GAHRAVEIEA LTPHSSYCVV AEIYQPMLDR RSQRSEERCV EIP |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于IL22RA2重组蛋白的3篇参考文献示例(注：以下内容为假设性示例，实际文献需通过学术数据库验证)：
---
1. **标题**: *"IL-22RA2 Acts as a Decoy Receptor to Inhibit IL-22-Driven Inflammation"*
**作者**: Smith A, et al.
**摘要**: 研究通过表达重组IL22RA2蛋白，证实其作为IL-22的诱饵受体，阻断IL-22与功能性受体IL-22Rα1的结合，从而抑制下游促炎信号通路，为治疗炎症性疾病提供潜在靶点。
2. **标题**: *"Recombinant IL22RA2-Fc Fusion Protein Alleviates Colitis in Murine Models"*
**作者**: Wang Y, et al.
**摘要**: 构建IL22RA2-Fc融合蛋白，在小鼠结肠炎模型中验证其治疗效果。结果显示，重组蛋白通过中和IL-22活性，显著减少肠道炎症和屏障损伤。
3. **标题**: *"Structural and Functional Characterization of Human IL22RA2 Expressed in HEK293 Cells"*
**作者**: Chen L, et al.
**摘要**: 在HEK293细胞中表达并纯化重组人IL22RA2.通过表面等离子共振(SPR)分析其与IL-22的高亲和力结合，揭示其调控IL-22/STAT3信号通路的分子机制。
---
**建议**：以上文献为示例，实际研究中请通过PubMed或Google Scholar搜索关键词(如“IL22RA2 recombinant”、“IL-22 decoy receptor”)获取最新文献，并优先选择高影响力期刊(如*Nature Immunology*、*Journal of Biological Chemistry*)的研究。
**Background of IL22RA2 Recombinant Protein**
Interleukin-22 receptor alpha 2 (IL22RA2), also known as IL-22 binding protein (IL-22BP), is a soluble receptor homolog belonging to the IL-10 receptor family. It functions as a natural antagonist of IL-22. a cytokine involved in mucosal immunity, tissue repair, and inflammatory responses. Unlike the membrane-bound IL-22 receptor complex (IL-22Rα1/IL-10Rβ), IL22RA2 lacks transmembrane and intracellular domains, enabling it to bind IL-22 with high affinity in extracellular spaces, thereby blocking its interaction with functional receptors.
IL22RA2 is primarily produced by dendritic cells, epithelial cells, and certain immune cells. Its expression is regulated by inflammatory signals, including TNF-α and IL-23. linking it to pathologies such as psoriasis, inflammatory bowel disease (IBD), and rheumatoid arthritis. Dysregulation of IL22RA2 has been implicated in both exaggerated and insufficient IL-22 activity, contributing to autoimmune disorders, chronic inflammation, and cancer progression. For instance, reduced IL22RA2 levels may exacerbate IL-22-driven epithelial hyperplasia, while its overexpression could impair antimicrobial defense.
Recombinant IL22RA2 protein is engineered for research and therapeutic applications. Produced via mammalian expression systems (e.g., HEK293 or CHO cells), it retains the ligand-binding domain, ensuring biological relevance. This protein is widely used to study IL-22 signaling mechanisms, assess its role in disease models, and develop IL-22-targeted therapies. In preclinical studies, recombinant IL22RA2 has shown potential in mitigating IL-22-mediated pathologies, offering a promising tool for modulating immune responses in inflammatory and neoplastic conditions.
Overall, IL22RA2 recombinant protein serves as a critical reagent for dissecting IL-22 biology and exploring therapeutic strategies to balance its dual roles in inflammation and tissue homeostasis.
×
